secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001193125-24-142317
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase raises $4.0M in registered direct offering and warrant inducement
----------------------------------------------------------------------------

- Offering of 1,672,452 shares (or pre-funded warrants) at $1.68/unit with Series A and B warrants.
- Warrant inducement: immediate exercise of 708,500 existing warrants at $1.68; repricing of 1,229,484 warrants.
- Series A/C warrants exercisable 12 months; Series B/D warrants exercisable 5 years from stockholder approval.
- Gross proceeds ~$4.0M; expected closing May 22, 2024; Maxim Group sole placement agent.
- Proceeds for general corporate purposes; stockholder approval required for warrant exercisability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524142317/0001193125-24-142317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524142317/d768660d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-142317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer